An Interview with Nachum Kaplan, Vice President of Microbiology at Affinium Pharmaceuticals
Download Your Copy
We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.
An Interview with Nachum Kaplan, Vice President of Microbiology at Affinium Pharmaceuticals on bacterial fatty-acid synthesis as a target for AFN-1252: a novel and selective-spectrum antibiotic for the treatment of Staphylococcal infection.
To continue reading this story get free access
Please note: That all fields marked with an asterisk (*) are required.